Literature DB >> 22155796

Karyometry in atypical endometrial hyperplasia: a Gynecologic Oncology Group study.

Peter H Bartels1, Francisco A R Garcia, Cornelia L Trimble, James Kauderer, John Curtin, Peter C Lim, Lisa M Hess, Steven Silverberg, Richard J Zaino, Michael Yozwiak, Hubert G Bartels, David S Alberts.   

Abstract

OBJECTIVES: Treatment for atypical endometrial hyperplasia (AEH) is based on pathologic diagnosis. About 40% of AEH is found to be carcinoma at surgery. This study's objective is to derive an objective characterization of nuclei from cases diagnosed as AEH or superficially invasive endometrial cancer (SIEC).
METHODS: Cases from GOG study 167A were classified by a central pathology committee as AEH (n=39) or SIEC (n=39). High resolution digitized images of cell nuclei were recorded. Features of the nuclear chromatin pattern were computed. Classification rules were derived by discriminant analysis.
RESULTS: Nuclei from cases of AEH and SIEC occupy the same range on a progression curve for endometrial lesions. Cases of AEH and SIEC both comprise nuclei of two phenotypes: hyperplastic characteristics and premalignant/neoplastic characteristics. The principal difference between AEH and SIEC is the percentage of premalignant/neoplastic nuclei. When this percentage approaches 50-60% superficial invasion is likely. SIEC may develop already from lesions at the low end of the progression curve.
CONCLUSIONS: AEH comprises cases which may constitute a low risk group involving <40% of AEH cases. These cases hold a percentage of <20% of nuclei of a preneoplastic phenotype. AEH cases from the central and high end of progression have >40% of nuclei of preneoplastic phenotype. Nuclei of the preneoplastic phenotype in AEH lesions are almost indistinguishable from nuclei in SIEC, where this percentage exceeds 60%. The percentage of nuclei of the preneoplastic phenotype in AEH esions might serve as criterion for assessment of risk for the development of invasive disease. Copyright Â
© 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22155796      PMCID: PMC4029110          DOI: 10.1016/j.ygyno.2011.12.422

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  25 in total

1.  Reproducibility of the diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study.

Authors:  Richard J Zaino; James Kauderer; Cornelia Liu Trimble; Steven G Silverberg; John P Curtin; Peter C Lim; Donald G Gallup
Journal:  Cancer       Date:  2006-02-15       Impact factor: 6.860

2.  Carcinogenesis and the hypothesis of phylogenetic reversion.

Authors:  Peter H Bartels; James Ranger-Moore; David Alberts; Lisa Hess; Marina Scarpelli; Rodolfo Montironi
Journal:  Anal Quant Cytol Histol       Date:  2006-10       Impact factor: 0.302

3.  Use of computerized morphometric analyses of endometrial hyperplasias in the prediction of coexistent cancer.

Authors:  C J Dunton; J P Baak; J P Palazzo; P J van Diest; M McHugh; E A Widra
Journal:  Am J Obstet Gynecol       Date:  1996-05       Impact factor: 8.661

4.  A difference in nuclear morphometry when frozen rather than fresh tissue is studied.

Authors:  J P Geisler; M C Wiemann; Z Zhou; G A Miller; H E Geisler
Journal:  Eur J Gynaecol Oncol       Date:  1997       Impact factor: 0.196

5.  Estimates of the worldwide incidence of 25 major cancers in 1990.

Authors:  D M Parkin; P Pisani; J Ferlay
Journal:  Int J Cancer       Date:  1999-03-15       Impact factor: 7.396

6.  Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study.

Authors:  Cornelia L Trimble; James Kauderer; Richard Zaino; Steven Silverberg; Peter C Lim; James J Burke; David Alberts; John Curtin
Journal:  Cancer       Date:  2006-02-15       Impact factor: 6.860

Review 7.  Endometrial hyperplasia/adenocarcinoma. a conventional approach.

Authors:  Michael T Mazur
Journal:  Ann Diagn Pathol       Date:  2005-06       Impact factor: 2.090

8.  Assessment of the risk on endometrial cancer in hyperplasia, by means of morphological and morphometrical features.

Authors:  J P Baak; E C Wisse-Brekelmans; J C Fleege; H W van der Putten; P D Bezemer
Journal:  Pathol Res Pract       Date:  1992-10       Impact factor: 3.250

Review 9.  Benign endometrial hyperplasia sequence and endometrial intraepithelial neoplasia.

Authors:  George L Mutter; Richard J Zaino; Jan P A Baak; Rex C Bentley; Stanley J Robboy
Journal:  Int J Gynecol Pathol       Date:  2007-04       Impact factor: 2.762

10.  Karyometry of the colonic mucosa.

Authors:  David S Alberts; Janine G Einspahr; Robert S Krouse; Anil Prasad; James Ranger-Moore; Peter Hamilton; Ayaaz Ismail; Peter Lance; Steven Goldschmid; Lisa M Hess; Michael Yozwiak; Hubert G Bartels; Peter H Bartels
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-12       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.